Development and in Vitro Evaluation of Dextrose Transdermal Patches as a Low-Cost Alternative to Intravenous Delivery
Overview
Objectives The purpose of this project was to evaluate the feasibility of transdermal patches as a cost-effective replacement for the intravenous (IV) delivery of dextrose to patients. Methods Prototype transdermal patches were fabricated containing dextrose at three different concentration levels. Each was subjected to an in vitro evaluation aligned with United States Pharmacopeia (USP) standards. Patches were applied to the bottom of a dissolution bath of distilled water, at 32 degrees Celsius and stirred by a paddle at 50 RPM, and samples were taken at three times: 0.5, 1.0, and 1.5 hours (N=216). The samples were 10x diluted in distilled water and analyzed for dextrose concentration using a blood glucometer. Correcting for volume changes, the cumulative dextrose present in the water bath at each time point was calculated and analyzed in comparison to IV rates of infusion (~12 g/hr +- 5%). Results Regression functions mapping the data (cumulative dextrose released vs. time) using the Higuchi model of diffusion show nonlinear release kinetics of the transdermal patches as opposed to the linear release kinetics of IV . This means transdermal patches are considerably less accurate (<70% accuracy) in matching the typical IV infusion rate than does an IV line (95% accuracy). However, the daily cost of using patches is only ~$10 whereas that of IV is ~$200. Ratios of accuracy to daily cost show that patches are nearly 15 times as cost-efficient than IV for delivery of dextrose. Conclusions Because transdermal patches are far more cost-efficient than IV delivery of dextrose, these patches constitute a feasible solution to replace costly IV administration of dextrose. This has revolutionary implications as transdermal patches, unlike IV lines, can be made accessible outside of the hospital, for potential use in malnourished developing countries, by hypoglycemics or diabetics, or even by athletes and the military.
Summary statement
I developed prototypes of novel transdermal patches and used in vitro evaluation to show they are feasible low-cost alternatives to intravenous (IV) treatment.
Help received
None. I designed and conducted the development of the prototypes and the experiments by myself.
Competition history
- CSEF 2019
Resources
Related projects
ISEF · 2016
Inexpensive, Portable Glucose Monitor for Diabetics via a Crosslinked Sensing Fluid
CSEF · 2019
Transdermal Lactate Collection with Agarose Gels for Noninvasive and Painless Monitoring of Patients
ISEF · 2024
Developing a Rapidly Dissolving, Biodegradable Microneedle Patch and Standard Curve for Minimally Invasive Filtration Marker Delivery and Point-of-Care Renal Analysis
ISEF · 2018
KetoPatch: A Novel Method for Early Detection of Diabetic KetoAcidosis
CSEF · 2017
Diabetes, A Bloody Mess: Non-Invasive Glucose Testing
ISEF · 2023
DiaVest II: A Non-Invasive Glucose Monitoring System for Diabetes Management
ISEF · 2019
A Novel Optical Diagnostic Method for Non-Invasive Detection of Blood Glucose Using Reverse Iontophoresis Modulation and Personalized Neural Networks
ISEF · 2025
The GlycoCharge: A Translational Spectrophotometric Apparatus for Noninvasive Glucose Monitoring in Type II Diabetics Using Correlated Electrolyte Concentrations
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects